Management of acute leukemia in adults.
The treatment of acute leukemia in adults, while not yet as successful as that in children with regard to either remission rate or prolongation of life, can now regularly result in at least 50% responses in acute myelocytic leukemia and 70-80% in acute lymphocytic leukemia. Intensive specific chemotherapy and supportive therapy throughout the resultant period of myelo and immuno-suppression are necessary to achieve these remission rates. Further investigations aimed at both prolonging the remissions so obtained and at improving the response rate further are essential.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006412:Hematopoietic Stem Cells; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology; D013997:Time Factors
D000970:Antineoplastic Agents; D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin